- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05599984
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin.
ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 350 adult participants will be enrolled in the study across sites worldwide.
In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 3 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Health and Ludwig Institute for Cancer Research /ID# 255174
-
Melbourne, Victoria, Australia, 3000
- Recruiting
- Peter MacCallum Cancer Ctr /ID# 259197
-
-
-
-
-
Jerusalem, Israel, 91120
- Recruiting
- Hadassah Medical Center-Hebrew University /ID# 255147
-
-
H_efa
-
Haifa, H_efa, Israel, 3109601
- Recruiting
- Rambam Health Care Campus /ID# 255059
-
-
Tel-Aviv
-
Ramat Gan, Tel-Aviv, Israel, 5265601
- Recruiting
- The Chaim Sheba Medical Center /ID# 254915
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East /ID# 259417
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 791-0280
- Recruiting
- National Hospital Organization Shikoku Cancer Center /ID# 261279
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 003-0804
- Recruiting
- Hokkaido Cancer Center /ID# 261278
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan, 606-8507
- Recruiting
- Kyoto University Hospital /ID# 259419
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 411-8777
- Recruiting
- Shizuoka Cancer Center /ID# 261277
-
-
Tokyo
-
Koto, Tokyo, Japan, 135-8550
- Recruiting
- The Cancer Institute Hospital Of JFCR /ID# 260132
-
-
Wakayama
-
Wakayama-shi, Wakayama, Japan, 641-8510
- Recruiting
- Wakayama Medical University Hospital /ID# 260131
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital /ID# 248940
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center /ID# 248936
-
-
Gyeonggido
-
Goyang-si, Gyeonggido, Korea, Republic of, 10408
- Recruiting
- National Cancer Center /ID# 248938
-
Seongnam, Gyeonggido, Korea, Republic of, 13496
- Recruiting
- CHA Bundang Medical Center /ID# 248939
-
-
Jeonranamdo
-
Hwasun-gun, Jeonranamdo, Korea, Republic of, 58128
- Recruiting
- Chonnam National University Hwasun Hospital /ID# 248943
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 03722
- Recruiting
- Yonsei University Health System Severance Hospital /ID# 248937
-
-
-
-
-
Madrid, Spain, 28050
- Recruiting
- Hospital Universitario HM Sanchinarro /ID# 258657
-
Madrid, Spain, 28034
- Recruiting
- Hospital Universitario Ramon y Cajal /ID# 257291
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Banner MD Anderson Cancer Ctr /ID# 260129
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope /ID# 259884
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Recruiting
- Yale School of Medicine /ID# 246647
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Recruiting
- Georgetown University Hospital /ID# 255352
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Recruiting
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 260130
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa Hospitals and Clinics /ID# 246638
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Hospital /ID# 246648
-
Detroit, Michigan, United States, 48201
- Recruiting
- Barbara Ann Karmanos Cancer In /ID# 261799
-
Grand Rapids, Michigan, United States, 49546-7062
- Recruiting
- START Midwest /ID# 251257
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University-School of Medicine /ID# 246286
-
-
New York
-
New York, New York, United States, 10065-6007
- Recruiting
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 246303
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke Cancer Center /ID# 246285
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- UH Cleveland Medical Center /ID# 246641
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73117
- Recruiting
- Univ Oklahoma HSC /ID# 250884
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tennessee Oncology, PLLC /ID# 246283
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas MD Anderson Cancer Center /ID# 246287
-
San Antonio, Texas, United States, 78229
- Recruiting
- South Texas Accelerated Research Therapeutics /ID# 248946
-
-
Utah
-
Salt Lake City, Utah, United States, 84112-5500
- Recruiting
- University of Utah /ID# 246640
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Recruiting
- Northwest Medical Specialties - Tacoma /ID# 262801
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- The laboratory values criteria must be met within 7 days prior to the first dose of study drug as per the protocol.
- QT interval corrected for heart rate (QTc) <= 450 msec (males) or <= 470 msec (females) using Fridericia's correction, and an ejection fraction of >= 50% as measured by echocardiogram or multigated acquisition (MUGA) scan at Screening.
- Part 1 only: Advanced recurrent or refractory solid tumors with potential SEZ6 expression including small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors (glioblastoma [GBM], IDH-wildtype Grade 4; oligodendroglioma, IDH-mutant, and 1p/19q-codeleted Grade 3; astrocytoma, IDH-mutant Grade 3 or Grade 4), neuroendocrine prostate cancer (NEPC), high-grade poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)s, large cell neuroendocrine carcinoma (LCNEC)s, SCLC transformed from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), atypical lung carcinoids, and other high-grade poorly differentiated NECs, who have progressed on or after standard of care (SoC) therapy and with no curative therapy available. For SCLC, participants must have histologically or cytologically confirmed SCLC that is relapsed or refractory following at least 1 prior platinum-containing chemotherapy.
- Part 2 only: Histologically or cytologically confirmed SCLC that is relapsed or refractory (R/R) following at least 1 prior platinum-containing chemotherapy and with no curative therapy available. For the purposes of this study, a line of therapy is defined as >= 1 complete cycle of either a single agent or combination of drugs, including any planned sequential therapy of various regimens.
- Part 3a only: Participants with R/R SCLC following at least 1 prior platinum-containing chemotherapy or R/R poorly differentiated NECs, e.g., NEPC, GEP-NECs, LCNECs, SCLC transformed from EGFR mutant Non-small cell lung cancer (NSCLC), atypical lung carcinoids, other high-grade poorly differentiated NECs.
- Part 3b only: Participants with R/R SCLC who have only progressed following a frontline regimen containing a platinum-based chemotherapy or R/R NECs, e.g., NEPC, GEP-NECs, LCNECs, SCLC transformed from EGFR mutant NSCLC, atypical lung carcinoids, other NECs.
- Part 4a only: Participants with R/R high-grade CNS tumors (GBM, IDH-wildtype Grade 4; oligodendroglioma, IDH-mutant, and 1p/19q-codeleted Grade 3; astrocytoma, IDH-mutant Grade 3 or Grade 4) who have progressed on SoC therapy and with no curative therapy options available.
- Part 4b only: Participants with R/R neuroendocrine tumors, including NEPC, GEP-NECs, LCNECs, SCLC transformed from EGFR mutant NSCLC, atypical lung carcinoids, and other high-grade poorly differentiated NECs, who have progressed on SoC therapy and with no curative therapy options available.
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for participants with extracranial solid tumors or Response Assessment for Neuro-Oncology (RANO)for participants with primary high-grade CNS tumors (GBM, IDH-wildtype Grade 4; oligodendroglioma, IDH-mutant, and 1p/19q-codeleted Grade 3; astrocytoma, IDH-mutant Grade 3 or Grade 4).
- Primary CNS tumors within 12 weeks from radiation therapy should have unequivocal progression as documented by either tumor recurrence predominantly outside of radiation field on magnetic resonance imaging (MRI) or confirmed on tumor biopsy.
- Participants with brain metastases from an extracranial solid tumor are eligible if the brain metastases as outlined in the protocol.
- Fresh or archival tumor tissue available for submission, for retrospective SEZ6 expression analysis as outlined in the protocol.
Exclusion Criteria:
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, nor any evidence of active ILD or pneumonitis.
- History of idiopathic pulmonary fibrosis or organizing pneumonia.
- Prior treatment with an antibody drug conjugate that consists of a Top1 inhibitor payload.
- Part 2 only: Prior treatment with a SEZ6-targeted antibody drug conjugate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: ABBV-706 Monotherapy Dose Escalation
Participants will receive escalating doses of ABBV-706 until doses for optimization are determined, as part of an approximately 1 year treatment period.
|
Intravenous (IV) Infusion
|
Experimental: Part 2: ABBV-706 Monotherapy Dose Optimization and Expansion
Participants with small cell lung cancer will receive varying doses of ABBV-706 in a randomized manner until the recommended phase 2 dose (RP2D) is achieved, as part of an approximately 1 year treatment period..
|
Intravenous (IV) Infusion
|
Experimental: Part 3a: ABBV-706 + Budigalimab
Participants will receive ABBV-706 in combination with budigalimab, as part of an approximately 1 year treatment period.
|
Intravenous (IV) Infusion
IV Infusion
Other Names:
|
Experimental: Part 3b: ABBV-706 + Platinum Chemotherapy
Participants will receive ABBV-706 in combination with carboplatin or cisplatin, as part of an approximately 1 year treatment period.
|
Intravenous (IV) Infusion
Intravenous infusion
Intravenous infusion
|
Experimental: Part 4a: ABBV-706 Monotherapy Dose Expansion CNS Tumors
Participants with relapsed/refractory (R/R) central nervous system (CNS) tumors will receive ABBV-706 as a monotherapy at or below the maximum tolerated dose (MTD) maximum administered dose (MAD), as part of an approximately 1 year treatment period.
|
Intravenous (IV) Infusion
|
Experimental: Part 4b: ABBV-706 Monotherapy Dose Expansion NECs
Participants with R/R neuroendocrine carcinomas (NECs) will receive IV Infused ABBV-706 as a monotherapy at or below the MTD/MAD, as part of an approximately 1 year treatment period.
|
Intravenous (IV) Infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Adverse Events (AE)
Time Frame: Up to Approximately 2 Years
|
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
|
Up to Approximately 2 Years
|
Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706
Time Frame: Up to Approximately 2 Years
|
Maximum observed serum/plasma concentration of ABBV-706.
|
Up to Approximately 2 Years
|
Time to Cmax (Tmax) of ABBV-706
Time Frame: Up to Approximately 2 Years
|
Time to Cmax of ABBV-706.
|
Up to Approximately 2 Years
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-706
Time Frame: Up to Approximately 2 Years
|
Terminal phase elimination half-life (t1/2) of ABBV-706.
|
Up to Approximately 2 Years
|
Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706
Time Frame: Up to Approximately 2 Years
|
Area under the serum/plasma concentration-time curve of ABBV-706.
|
Up to Approximately 2 Years
|
Antidrug Antibodies (ADAs)
Time Frame: Up to Approximately 2 Years
|
Incidence and concentration of anti-drug antibodies.
|
Up to Approximately 2 Years
|
Neutralizing Antibodies (nAbs)
Time Frame: Up to Approximately 2 Years
|
Incidence and concentration of neutralizing antibodies.
|
Up to Approximately 2 Years
|
Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors
Time Frame: Up to Approximately 2 Years
|
Objective response is defined as participants achieving a confirmed best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 for for extracranial solid tumors per investigator assessment.
|
Up to Approximately 2 Years
|
Recommended Phase 2 Dose (RP2D) of ABBV-706
Time Frame: Up to Approximately 2 Years
|
The RP2D will be determined using all available information, including, but not limited to, AEs, dose-limiting toxicities, pharmacokinetic parameters, clinical laboratory tests, and efficacy measures.
|
Up to Approximately 2 Years
|
Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors
Time Frame: Up to Approximately 2 Years
|
Objective response is as participants achieving a confirmed best overall response of CR and PR according to Response Assessment for Neuro-Oncology (RANO), version 1.1 for CNS tumors per investigator assessment.
|
Up to Approximately 2 Years
|
Duration of response (DOR) for Participants with Confirmed CR/PR
Time Frame: Up to Approximately 2 Years
|
For participants achieving a confirmed CR/PR, DOR is defined as the time from the initial response of CR/PR to disease progression or death of any cause, whichever occurs earlier.
|
Up to Approximately 2 Years
|
Percentage of Participants with Clinical Benefit
Time Frame: Up to Approximately 2 Years
|
Clinical benefit is defined as a participant achieving CR/PR, or Stable Disease (SD).
|
Up to Approximately 2 Years
|
Progression-Free Survival (PFS)
Time Frame: Up to Approximately 2 Years
|
PFS is defined as time from first study treatment to a documented disease progression, as determined by the investigator, or death due to any cause, whichever occurs earlier.
|
Up to Approximately 2 Years
|
Overall survival (OS)
Time Frame: Up to Approximately 2 Years
|
OS is defined as time from first study treatment to death due to any cause.
|
Up to Approximately 2 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M23-385
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on ABBV-706
-
Gedeon Richter Plc.RecruitingPrader-Willi SyndromeUnited States, Spain, Czechia, Italy, France
-
AbbVieCompletedCystic FibrosisUnited States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
-
AbbVieTerminated
-
AbbVieCompletedCoronaVirus Disease-2019 (COVID-19)United States, Hungary, Israel, Netherlands, Puerto Rico
-
AbbVieRecruitingHealthy Volunteers | Generalized Anxiety Disorder (GAD) | Bipolar Disorder (BPD)United States
-
AbbVieCompletedHuman Immunodeficiency Virus (HIV)United States, Puerto Rico
-
AbbVieCompleted
-
AbbVieActive, not recruitingB-cell LymphomaIsrael, Puerto Rico, Turkey
-
AbbVieCompletedAdvanced Solid Tumors CancerUnited States, France, Japan, Puerto Rico, Spain, Taiwan
-
AbbVieWithdrawnParkinson's DiseaseUnited States, Puerto Rico